Gilteritinib + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Trial Timeline
Jan 10, 2017 → Feb 19, 2024
NCT ID
NCT02927262About Gilteritinib + Placebo
Gilteritinib + Placebo is a phase 2 stage product being developed by Astellas Pharma for Acute Myeloid Leukemia (AML). The current trial status is completed. This product is registered under clinical trial identifier NCT02927262. Target conditions include Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia (AML) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02997202 | Phase 3 | Completed |
| NCT02927262 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)